Key facts
- This page summarizes Gil M. Labrucherie's Form 4 filing for NEKTAR THERAPEUTICS (NKTR).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 17 May 2022, 21:32.
Gil M. Labrucherie - 15 May 2022 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)
- Reporting relationship
- SVP, COO & CFO
- Issuer ticker
- NKTR
- Reported as of
- 15 May 2022
- Net transaction value
- -$68,920
- SEC form
- 4
- Accepted by SEC
- 17 May 2022, 21:32:02 UTC
- Prior SEC filing
- 09 May 2022
- Next SEC filing
- 27 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- Mark A. Wilson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gil M. Labrucherie filed Form 4 for NEKTAR THERAPEUTICS (NKTR) on 17 May 2022.
Change
- Previous filing in this sequence was filed on 09 May 2022.
- Current net transaction value: -$68,920.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NKTR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +28,750
- Change %
- +9.5%
- Price
- $0.000000
- Shares after
- 330,353
- Date
- 15 May 2022
- Ownership
- Direct
- Footnotes
- F1, F2, F3
NKTR
transaction
Common Stock
Sale
- Transaction value
- $68,920
- Shares
- -17,448
- Change %
- -5.3%
- Price
- $3.95
- Shares after
- 312,905
- Date
- 16 May 2022
- Ownership
- Direct
- Footnotes
- F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 14, 2018 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.
Footnote F2
The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on May 13, 2022. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (May 15, 2022) following the date that the performance-based vesting requirement was satisfied.
Footnote F3
This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
Footnote F4
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Footnote F5
This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.